Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, BioNTech SE (BNTX) has a Wall Street consensus price target of $136.80, based on estimates from 24 covering analysts. With the stock currently trading at $110.23, this represents a potential upside of +24.1%. The company has a market capitalization of $27.66B.
Analyst price targets range from a low of $113.00 to a high of $155.00, representing a 31% spread in expectations. The median target of $140.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BNTX trades at a trailing P/E of -33.7x. Analysts expect EPS to grow +3.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BNTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for BNTX is $136.8, representing 24.1% upside from the current price of $110.23. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BNTX has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $136.8 implies 24.1% upside from current levels.
BNTX's current price is $110.23 with a consensus target of $136.8 (24.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $155 for BNTX, while the most conservative target is $113. The consensus of $136.8 represents the median expectation. These targets typically reflect 12-month expectations.
BNTX is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BNTX stock forecast based on 24 Wall Street analysts shows a consensus price target of $136.8, with estimates ranging from $113 (bear case) to $155 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BNTX, with a "Buy" consensus rating and $136.8 price target (24.1% upside). 20 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BNTX analyst price targets range from $113 to $155, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $136.8 consensus represents the middle ground.